GlassScriptPhysician profile
Clint P Malcom
NPI 1689620650
$4,372.06
in general payments reported to CMS, 2019-2025
20 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $1,157 · 2023: $1,343 · 2024: $1,116 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Education: $53.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.03 |
| Education | $53.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,164.74 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $762.63 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $514.54 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $387.32 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.92 | 2021-2024 | Caplyta |
| Lundbeck LLC | $222.70 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $201.11 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $191.59 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $136.40 | 2021-2024 | Trintellix |
| Corium, LLC | $117.23 | 2022-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $107.29 | 2023-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $76.20 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $56.84 | 2022 | |
| Vanda Pharmaceuticals INC. | $29.22 | 2021 | |
| Eisai INC. | $21.50 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.83 | 2024 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $14.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.97 | 2024 | Invega Sustenna |
| Arbor Pharmaceuticals, INC. | $13.24 | 2021 | |
| Allergan, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clint Malcom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.